Sign in
Taking people in CzechiaPhase 2

Grafalon for children and young adults recently diagnosed with type 1 diabetes

Compares 2 Grafalon doses in recently diagnosed type 1 diabetes, to protect beta cells.

Key facts

Who runs it
Institute For Clinical And Experimental Medicine
Where
Prague and Prague 10, CzechiaSee the 2 sites
Trial code
Registry title
Grafalon®therapy within 12 weeks of Type 1 diabetes (T1D) diagnosis in children and young adults to prevent the loss of residual beta cell function: a randomised, double-blind, placebo-controlled dose finding study Acronym: GIRO T1D
Status
Recruiting
Phase
Phase 2
People taking part
18 people, planned
Started
4 Jun 2024
Expected to end
31 Dec 2028
Type of study
Interventional
Record updated
6 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young adults with recently diagnosed type 1 diabetes. It tests two doses of Grafalon (ATLG) against placebo to protect insulin-making cells.

Age
Up to 64 years (the record gives only the maximum age).
Sex
All sexes can join.
Disease stage
Recent onset type 1 diabetes. The title says treatment starts within 12 weeks of diagnosis.
Earlier treatment
Cannot have had other medicines or herbal products that affect the immune system in the 90 days before screening. Cannot have had a vaccination in the 4 weeks before randomization.

Main reasons for not taking part

  • HIV, HTLV I/II, hepatitis B or hepatitis C infection
  • Positive viral PCR test for EBV, CMV or COVID
  • Any past or current cancer
  • Pregnant or breastfeeding women, or women who want to become pregnant during the study
  • BMI over 35 kg/m2, or another form of diabetes

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • from the beginning of Screening to Visit 14

Who cannot take part

  • History of recurrent (e.g., several times a year) of severe (e.g., pneumonia) or chronic infections or conditions predisposing to chronic infections 2. History of severe systemic fungal infection within the past 12 months prior to screening unless treated and resolved with appropriate documented therapy 3. Vaccination within 4 weeks before randomization 4. Positive Viral PCR for EBV, CMV, COVID 5. Patients with HIV or HTLV I/II infection or HepB/C 6. Receipt of any other concomitant medications or herbal products that can influence the immune system within 90 days prior to screening 7. History of pancreatitis (acute or chronic) 8. Any past or current diagnosis of malignant neoplasms 9. Known impairment of the immune system, except for T1D, coeliac disease, alopecia, autoimmune antibodies not considered clinical important (e.g. thyroid antibodies without any clinically important thyroid disease or well-balanced Hashimoto’s disease), and vitiligo 10. Patients with a psychiatric condition (e.g., severe anxiety, psychosis) that would interfere with the study as determined by the primary investigator. Stable psychiatric conditions such as chronic anxiety or depression will be allowed. 11. Patients with known allergy to one or more of the study drug components or rabbit proteins. 12. Female patients who are pregnant, lactating, or who want to get pregnant during the study period. 13. Patients with a history of alcohol or any psychoactive substance abuse or dependence (including alcohol but excluding nicotine and caffeine). 14. Patients with any other significant chronic disease, according to the investigator discretion, exclude rare forms of diabetes (MODY) according to history and clinical judgement. 15. Obesity (BMI more than 35 kg/m2) 16. Other forms of diabetes 17. Patients unable or unwilling to comply with the protocol

Where in Czechia

  • Institute for Clinical and Experimental MedicinePrague, CzechiaTaking people
  • Fakultní Nemocnice Královské VinohradyPrague 10, CzechiaTaking people

About the trial

What the trial wants to find out

To assess the efficacy and safety of two different ATLG dosages in the treatment of patients with recent onset Type 1 Diabetes.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Grafalon®therapy within 12 weeks of Type 1 diabetes (T1D) diagnosis in children and young adults to prevent the loss of residual beta cell function: a randomised, double-blind, placebo-controlled dose finding study Acronym: GIRO T1D
Plain-language title
Grafalon for children and young adults recently diagnosed with type 1 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
6 May 2026